durvalumab,oleclumab
astrazeneca
['carboplatin', 'synergy', 'durva', 'paclitaxel', 'oleclumab', 'tnbc', 'increase,(-increased)']
synergy ph2 trial of durvalumab, paclitaxel, carboplatin +/- oleclumab (anti-cd73 inhibiting the immunosuppressive adenosine generation) as 1l for #atnbc adding oleclumab to chemo-io did not increase clinical benefit (independent of pd-l1/cd73)
#esmo22 
Scientific Communication Manager | Passionate about molecular oncology, clinical and translational research | Photo and music enthusiast | Tweets are mine